Form 4: Galectin Therapeutics Director James Czirr Reports Stock Sales

James Czirr, a director of Galectin Therapeutics, reported the sale of common stock through 10X Fund, LP on April 22 and 23, 2024.

Summary

• James Czirr, a director at Galectin Therapeutics, reported the sale of company stock.
• The transactions occurred on April 22 and April 23, 2024.
• A total of 21,323 shares were sold on April 22 at a price of $3.06 per share.
• An additional 3,677 shares were sold on April 23, also at $3.06 per share.
• These sales were executed by 10X Fund, LP, where James C. Czirr serves as the manager of 10X Capital Management, LLC, the general partner.
• Following these transactions, 10X Fund, LP beneficially owns 5,922,207 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, reporting stock sales by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transactions.

Industry Context

Sales by company directors are a common occurrence and are publicly disclosed to maintain transparency in the market. Investors often monitor these transactions for insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• The stock sales by a director could be perceived negatively by some shareholders, potentially leading to a slight decrease in investor confidence.

Key Dates